Published October 22, 2026 · Compiled from the S-1/A filed on SEC EDGAR on 2026-10-20 and the Quintarthai IPO calendar. Quoted passages are the filing's own words.

Lycia Therapeutics, Inc. (LYCA) IPO: what the S-1/A filing says

Lycia Therapeutics, Inc. filed an S-1/A with the SEC on 2026-10-20 in connection with its US listing.

In the Quintarthai IPO calendar: status Upcoming, exchange NASDAQ, expected listing date Oct 23, 2026.

Use of proceeds (quoted from the filing)

• “We estimate that the net proceeds from this offering will be approximately $227.8 million, or approximately $262.7 million if the underwriters exercise their option to purchase additional shares in full, based on the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated…”
• “Similarly, each increase or decrease of 1.0 million shares in the number of shares of our common stock offered would increase or decrease, as applicable, the net proceeds that we receive from this offering by $15.8 million, assuming that the assumed initial public offering price remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering…”
• “Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities as of the date of this prospectus, together with the estimated net proceeds from this offering, will be sufficient for us to fund our projected operating expenses and capital expenditures into the second half of 2029.”

Source: S-1/A on SEC EDGAR · IPO research page: LYCA.

Research and analysis only — not investment advice, not a recommendation to apply or avoid.